Navigation Links
Einstein researchers discover gene mutations linked to longer lifespans
Date:3/4/2008

March 4, 2008 (Bronx, NY) Mutations in genes governing an important cell-signaling pathway influence human longevity, scientists at the Albert Einstein College of Medicine of Yeshiva University have found. Their research is described in the March 4 issue of the Proceedings of the National Academy of Sciences.

The report is the latest finding in the Einstein researchers ongoing search for genetic clues to longevity through their study that by now has recruited more than 450 Ashkenazi (Eastern European) Jews between the ages of 95 and 110. Descended from a small founder group, Ashkenazi Jews are more genetically uniform than other groups, making it easier to spot gene differences that are present. In 2003, this study resulted in the first two longevity genes ever identifiedfindings that have since been validated by other research.

The present study focused on genes involved in the action of insulin-like growth factor (IGF-I), a hormone that in humans is regulated by human growth hormone. Affecting virtually every cell type in the body, IGF-I is crucially important for childrens growth and continues contributing to tissue synthesis into adulthood. The IGF-I cell-signaling pathway is triggered when IGF-I molecules circulating in blood plasma latch onto receptors on the surface of cells, causing a signal to be sent to the cells nucleus that may, for example, tell that cell to divide.

Animal research had shown that mutations to genes involved in the IGF-I signaling pathway cause two effects: Affected animals have impaired growth but also longer life spans. So the Einstein scientists reasoned that altered signaling in this pathway might also influence human longevity. To find out, they analyzed IGF-I-related genetic variations in 384 Ashkenazi Jewish centenarians. And since plasma levels of IGF-I do not reflect their levels at a younger age, the researchers also looked at two other groups: the children of these centenarians, and a control group consisting of Ashkenazi Jews the same age as the centenarians children but with no family history of longevity.

Remarkably, the female children of the centenarians had IGF-I plasma levels that were 35 percent higher than female controlsperhaps a sign that the body was compensating for a glitch in IGF-I signaling by secreting increased amounts of the hormone. That suspicion was strengthened by two other findings: the daughters of centenarians were 2.5 cm shorter than female controls; and when the researchers analyzed the gene coding for the IGF-I cell-surface receptor molecule to which the IGF-I hormone binds, the receptor genes of centenarians and their daughters were much more likely to have a variety of mutations than were the receptor genes of the controls.

Our findings suggest that, by interfering with IGF-I signaling, these gene mutations somehow play a role in extending the human life span, as they do in many other organisms, says Dr. Nir Barzilai, senior author of the study and director of the Institute for Aging Research at Einstein.

Dr. Barzilai notes that a drug that decreases IGF-I action is currently being tested as a cancer treatment and could be useful in delaying aging. Since the subjects in our study have been exposed to their mutations since conception, it is not clear whether people would need such a therapy throughout life or if it could help people who received it at a later time.


'/>"/>

Contact: Karen Gardner
kgardner@aecom.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related medicine news :

1. NIH awards Einstein multimillion dollar grant to extend studies of exceptional longevity
2. Albert Einstein Healthcare Network Turns to InterviewDirect to Qualify Job Candidates
3. Einstein scientists treat cancer as an infectious disease -- with promising results
4. Testing delays cause severe AIDS complications, Einstein researchers find
5. Sens. Kerry, Boxer and Feinstein call on FDA to Establish Maximum Level for Lead in Lipstick
6. Johnson City Medical Center Begins Offering Einstein Bros. Menu Items at Second On Campus Location
7. Einstein honors Dr. Stanley Nathenson with Marshall S. Horwitz Faculty Prize for Research Excellence
8. Stanford researchers find culprit in aging muscles that heal poorly
9. UCLA researchers identify markers that may predict diabetes in still-healthy people
10. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
11. Bipolar disorder relapses halved by Melbourne researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The American ... to become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer ... Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the ... national organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps ... provides a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE ... team that developed an innovative way to use nonlinear ... the delivery of new drugs. ... Clinical Dermatology Conference will show how researchers from BioPharmX ... Harvard Medical School used a suite of imaging techniques ...
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
(Date:10/4/2017)... Oct. 4, 2017  South Korean-based healthcare product Development ... aide "cprCUBE" on Kickstarter. The device will educate the ... arrests with better efficiency compared to the dated and ... feedback on efficacy of the compression for a more ... a goal to raise $5,000. ...
Breaking Medicine Technology: